The core activity of RocketVax AG is the development and research of vaccines, particularly against Covid-19. The company focuses on developing vaccines that guarantee better immunity and can be easily administered through the nose. It is also working on improving Corona vaccine protection and plans to develop new vaccines.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Development of next-generation vaccines based on live-attenuated virus technology for established and new indications, focused on infectious diseases and unmet medical needs.
Development of SARS-CoV-2 vaccine candidates
Development of SARS-CoV-2 vaccine candidates RVX-sCPD9 and RVX-OTS as well as OTS-228, with preclinical data on safety, efficacy, stability and transmission-blocking immunity.
Nasal vaccine development
Development of a needle-free intranasal vaccine candidate against SARS-CoV-2, focused on easy administration, local immunity, reduced transmission and broad variant coverage.
Vaccine platform technology
Rational genetic design and proprietary vaccine platform technology for generating attenuated viruses, described as applicable to coronaviruses, influenza, flaviviruses, pneumoviruses, alphaviruses and herpes.